{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.6","upperLimit":"39.7","value":"37.3"},{"groupId":"OG001","lowerLimit":"37.7","upperLimit":"46.2","value":"42.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"337"}],"units":"Participants"}],"description":"The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs \\> 12 months). The median duration of follow-up is calculated by the reverse Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis","id":"OG000","title":"Paclitaxel and Carboplatin Chemotherapy"},{"description":"All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis","id":"OG001","title":"Paclitaxel and Carboplatin Chemotherapy With Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"All patients who were enrolled between December 10, 2007 and August 26, 2011 and received paclitaxel and carboplatin (with or without bevacizumab) (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).","reportingStatus":"POSTED","timeFrame":"The time frame is 82.5 months (median duration of follow-up).","title":"To Determine if the Addition of Bevacizumab Increases the Duration of Overall Survival Relative to Second-line Paclitaxel and Carboplatin Alone in Patients With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Primary or Fallopian Tube Cancer","type":"PRIMARY","unitOfMeasure":"Months"}